Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland

Tripep shares plummet as HIV drug disappoints

Share this article

18:10 CEST+02:00
Shares in Swedish biotech company Tripep AB crash dived after the company said it will probably scrap its alphaHGA HIV-inhibiting drug after trials in Thailand showed "no significant decrease of the HIV-levels in the patients' serum".

At 1.20 pm Tripep was down 65% at 4.62 kronor, while the OMX Stockholm was down 0.53% at 342.90.

"Naturally we are very disappointed," said Tripep. "A study report will be prepared but right now it is hard to see a continuation of the alphaHGA project".

Tripep's share price went vertical in January, reaching a high of 17.90 kronor amid optimism surrounding the trials in Thailand.

Tripep said it will now focus its research and resources on Hepatitis C.

AFX

Get notified about breaking news on The Local

Share this article

From our sponsors

The ‘fairytale' boarding school nestled in a Swedish village

The words ‘boarding' and ‘school' often summon images of strict teachers, drab dormitories and downcast children. That image couldn't be further from reality at Sigtunaskolan Humanistiska Läroverket (SSHL), where boarders describe the ‘fairytale' school as a home away from home.

Advertisement